Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

medRxiv logoLink to medRxiv
[Preprint]. 2021 Mar 12:2021.03.10.21253317. [Version 1] doi: 10.1101/2021.03.10.21253317

Type I, II, and III interferon signatures correspond to COVID-19 disease severity

Myung-Ho Kim, Shadi Salloum, Jeffrey Y Wang, Lai Ping Wong, James Regan, Kristina Lefteri, Zachary Manickas-Hill; MGH COVID-19 Collection & Processing Team, Jonathan Z Li, Ruslan I Sadreyev, Xu G Yu, Raymond T Chung
PMCID: PMC7987053  PMID: 33758894

Abstract

We analyzed the plasma levels of interferons and cytokines, and the expression of interferon-stimulated genes in peripheral blood mononuclear cells in COVID-19 patients with different disease severity. Mild patients exhibited transient type I interferon responses, while ICU patients had prolonged type I interferon responses with hyper-inflammation mediated by interferon regulatory factor 1. Type II interferon responses were compromised in ICU patients. Type III interferon responses were induced in the early phase of SARS-CoV-2 infection, even in convalescent patients. These results highlight the importance of type I and III interferon responses during the early phase of infection in controlling COVID-19 progression.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from medRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES